DSM-Firmenich AG (DSFIR.AS)

Overall impact
A (88)

Commentary

Royal DSM is a leader for overall positive impact. With an 'A' rating of 87.8 for overall impact (98th percentile compared to all companies), Royal DSM ranks 2nd out of 37 industry peers, behind Novozymes, and ahead of Minerals Technologies, GelTech Solutions, Trecora Resources and 32 others. On top material causes for Royal DSM's industry (Chemicals), Royal DSM performs well in Sustainable Use of Water (95.6 score), Clean Water Access (95.8), Sanitation Access (95.9) and 9 other causes where it received an 'A' score and performs poorly in Child and Maternal Health (24.9 score), Child and Maternal Health (27.3) and Child and Maternal Health (18.0).
Screens
Advertising
Alcohol
Alcohol - responsible marketing
Animal treatment
Anti-abortion support
Anti-personnel mines
Antisemitism
Arctic drilling
Banned pesticides and chemicals
Biological and chemical weapons
Carbon emissions intensity
Child safety
Cluster munitions
Coal
Contraceptives
Controversial weapons
Deforestation - financing
Deforestation - supply chain
Depleted uranium
Discrimination controversies
Electrical utility
Endangered wildlife
Environmental controversies
EU sanctions list
Factory farming
Firearms
Food commodity derivatives
For-profit health care
Fur
Gambling
Genetic engineering
Health-related controversies
Human rights controversies
Human trafficking
ILO Conventions
Interest-based products
Interest-bearing debt
Interest-bearing securities
Iran
Land use and biodiversity
Military contracting
Misleading communication
Music
Myanmar
Non-sustainable palm oil
Norges Bank exclusion list
Northern Ireland (Macbride)
North Korea
No SBTI commitment
Nuclear
OECD Guidelines
Oil and gas
Opioid controversies
Oppressive governments
Palestinian human rights
Pharma controversies
Pornography
Predatory lending
Prison involvement
Privacy breaches
Pro-life
Russia
Single-use plastic
Stem cell research
Sudan
Syria
Tar sands
Thermal coal
Tobacco
Tobacco - GICS
UK sanctions list
Undermining US elections
UN Global Compact
UN Guiding Principles
US OFAC sanctions list
Weapons
Impact
Cause DSFIR.AS
Peer rank
Overall impact

Log in to view this information

Screens
Advertising
Alcohol
Alcohol - responsible marketing
Animal treatment
Anti-abortion support
Anti-personnel mines
Antisemitism
Arctic drilling
Banned pesticides and chemicals
Biological and chemical weapons
Carbon emissions intensity
Child safety
Cluster munitions
Coal
Contraceptives
Controversial weapons
Deforestation - financing
Deforestation - supply chain
Depleted uranium
Discrimination controversies
Electrical utility
Endangered wildlife
Environmental controversies
EU sanctions list
Factory farming
Firearms
Food commodity derivatives
For-profit health care
Fur
Gambling
Genetic engineering
Health-related controversies
Human rights controversies
Human trafficking
ILO Conventions
Interest-based products
Interest-bearing debt
Interest-bearing securities
Iran
Land use and biodiversity
Military contracting
Misleading communication
Music
Myanmar
Non-sustainable palm oil
Norges Bank exclusion list
Northern Ireland (Macbride)
North Korea
No SBTI commitment
Nuclear
OECD Guidelines
Oil and gas
Opioid controversies
Oppressive governments
Palestinian human rights
Pharma controversies
Pornography
Predatory lending
Prison involvement
Privacy breaches
Pro-life
Russia
Single-use plastic
Stem cell research
Sudan
Syria
Tar sands
Thermal coal
Tobacco
Tobacco - GICS
UK sanctions list
Undermining US elections
UN Global Compact
UN Guiding Principles
US OFAC sanctions list
Weapons
Impact trend

Change in rating for overall impact

Log in to view this information

DSFIR.AS Price
$97.88
Last available end-of-day price. Full disclosure
Revenue
$13.08 billion
Market cap
$29.20 billion
Public/private
Public
Hypothetical historical growth of $10,000
Historical performance
Company
Employees
27,926
Sector
Materials
Industry
Chemicals
Sub-industry
Diversified Chemicals
SASB industry
Chemicals
Headquarters
Switzerland
Share classes
DSFIR.AS
RDSMY
Description
DSM-Firmenich AG provides solutions for nutrition, health, and beauty businesses in the Switzerland, Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. It operates through Perfumery & Beauty; Taste, Texture & Health; Health, Nutrition & Care; and Animal Nutrition & Health segments. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients. The Taste, Texture & Health segment provides food and beverages solutions, including flavors, natural extracts, and sugar reduction; and food enzymes, cultures, hydrocolloids, proteins, natural colorants, nutritional ingredients, premixes and yeast extracts solutions. The Animal Nutrition & Health segment offers animal proteins, as well as vitamins, performance solutions, and data-driven precision services for the animal production industry. The Health, Nutrition & Care segment provides solutions for the early life nutrition, dietary supplement, pharmaceutical, biomedical materials, and nutrition improvement markets. This segment offers vitamins, nutritional lipids, minerals, carotenoids, botanical nutraceuticals, digestive enzymes, probiotics and prebiotics, active pharmaceutical ingredients, as well as a range of biomedical solutions; premix, market-ready solutions, and personalized nutrition solutions; and regulatory affairs and formulation expertise services, and customized solutions. The company was founded in 1902 and is based in Kaiseraugst, Switzerland.
Material causes
Ethos considers the following causes material for DSM-Firmenich AG, based on its industry sub-industry Diversified Chemicals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.